Artivila
Latest round
- Series A
Last raised
- Jun 2026
Total raised
- Undisclosed
Investors
- 4
About Artivila
, dba Artivila, is a biotechnology company that engages in the research and development of drugs for neuro-degenerative diseases, cancers and autoimmune diseases through AI powered drug discovery engine. The founder of the company, Dr. Mike Zhu, received a doctor degree from University of Fribourg and was the principal Investigator at Celgene, the principal Investigator at Avila Therapeutics and the principal Scientist at Pfizer. Dr. Mike Zhu has more than 19 years of drug discovery experience, especially in the fields of data analysis, AI / ML approach, drug design, cheminformatics and computational chemistry. The co-founder of the company, Dr. David Niu, finished a doctor degree from New York University and was the vice president at Silicon Therapeutics and the director of Chemistry at Celgene. Dr. David Niu participated in over 10 projects that advanced into clinical stages, which includes the 3rd generation EGFR inhibitor, an HCV drug, and several clinical candidates in Celgene. The company's main business is an AI-driven R&D platform eLead, it enables developers to targets search, targets validation, lead discovery and optimization, candidates selection, IND enabling and clinical trials. Besides, the company focuses on the development of drugs for neurodegenerative diseases, autoimmune diseases and oncology. The company generates revenue from providing AI-driven R&D platform for its clients.
Who invested in Artivila
4 investors across 2 rounds
See all investors in Artivila
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Artivila
Who invested in Artivila?
Artivila has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Artivila raised?
Artivila has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Artivila last raise money?
Artivila's most recent round on record is a Series A, in Jun 2026.
What does Artivila do?
, dba Artivila, is a biotechnology company that engages in the research and development of drugs for neuro-degenerative diseases, cancers and autoimmune diseases through AI powered drug discovery engine.
Where is Artivila headquartered?
Artivila is headquartered in Shenzhen, China.
Which VCs invest in companies like Artivila?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Artivila's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Artivila? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.